Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Venus Remedies is currently trading at Rs. 299.50, up by 9.90 points or 3.42% from its previous closing of Rs. 289.60 on the BSE.
The scrip opened at Rs. 290.60 and has touched a high and low of Rs. 306.00 and Rs. 290.60 respectively. So far 47395 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 316.00 on 25-Oct-2012 and a 52 week low of Rs. 141.05 on 22-Dec-2011.
Last one week high and low of the scrip stood at Rs. 316.00 and Rs. 273.60 respectively. The current market cap of the company is Rs. 293.52 crore.
The promoters holding in the company stood at 34.21% while Institutions and Non-Institutions held 14.43% and 51.36% respectively.
Venus Remedies has received its first patent from Mexico for ‘Vancoplus’, a novel antibiotic formulation to Combat Methicillin Resistant Staphylococcus Aureus (MRSA) infections. The patent has been granted from the Mexico Patent office and is valid till February 2026.
Receiving a paten grant from Mexico for the research product Vancoplus at this point in time when the frequency of MRSA strains is growing high (50-85%) in Mexico, is a great achievement for the company. Vancoplus will prove to be the best known remedy to control MRSA, VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria in a situation wherein around 3 to 6 percent of the population carries the community form of MRSA.
As per the CDC reports published in the Journal of the American Medical Association in 2010, MRSA infections are constantly on the rise in the community and resistance against antibiotics with nearly 48% of S. aureus isolates were resistant to oxacillin (MRSA), and 49% were resistant to levofloxacin; 33% of Enterococcus faecium isolates were resistant to yancomycin and so on.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1504.75 |
| Dr. Reddys Lab | 6045.00 |
| Cipla | 1540.70 |
| Zydus Lifesciences | 1096.45 |
| Lupin | 1607.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
